| |
 |
 |
 |
 |
 |
 |
 |
June 1, 2006
Completion of Reexamination of the Basic US Patent on
NFκB Decoy Oligonucleotide
-Decision to Maintain Patent- |
 |
|
|
AnGes MG, Inc. is pleased to announce the completion in the US of the
reexamination of NFκB decoy oligonucleotide’s basic patent covering treatment for
inflammatory diseases, and that a reexamination certificate (US 6,262,033 C1) has
recently been published.
Reexamination of this patent had been under way at the US Patent and Trademark
Office, following a reexamination request made by an anonymous third party in
December 2001. (A “reexamination request” is almost equivalent to an opposition
system that was previously in place in Japan.) As a result, the patentability of
NFκB decoy oligonucleotide, a drug currently under development at our company,
has been reconfirmed, and the decision was made to maintain the said patent.
The reconfirmation of the patentability of this basic patent has shown that the rights
to NFκB decoy oligonucleotide which AnGes MG possesses are rock-solid.
Moreover, this patent will continue to support our development project.
No other request has been filed, for reexamination, opposition or invalidation trial, in
countries other than the US in which the drug’s patent has been granted, such as
Japan or Europe, and relevant rights are being effectively maintained.
AnGes MG has been filing additional patent applications for the drug’s use in other
diseases such as atopic dermatitis, asthma, organ transplantation, psoriasis and
rheumatoid arthritis. We continue to make efforts to expand the scope of the
drug’s clinical application. |
|
|
